• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More or Call (407) 374-6986

Wednesday 12/12/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

ARTH

  • 1:18 PM

    FRAMINGHAM, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) — Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of liquid, gel and solid hemostatic and wound care devices, today announced topline data for its irritation/sensitization patch test study of AC5™ Topical Gel (AC5)1. The study was designed to address a request by the Food and Drug Administration (FDA or “the Agency”). These topline results indicate that AC5 is neither an irritant nor a sensitizer. Additionally, no immunogenic response and no

    Read more
  • 2:09 PM

    FRAMINGHAM, Mass., June 15, 2018 (GLOBE NEWSWIRE) — Arch Therapeutics, Inc. (OTCQB:ARTH) (“Arch” or the “Company”), developer of liquid, gel and solid hemostatic and wound care devices, announced today that it has completed enrollment for its human skin sensitization study and that applications of the Company’s AC5™ Topical Gel are underway for all subjects. The study is anticipated to conclude during the third quarter. Terrence W. Norchi, MD, President and CEO of Arch, said, “This study is an important component of

    Read more
  • 3:18 PM

    FRAMINGHAM, Mass., Sept. 12, 2017, ARTH, (GLOBE NEWSWIRE) — Arch Therapeutics, Inc. (OTCQB:ARTH) (“Arch” or the “Company”), developer of novel liquid, gel and solid hemostatic and wound care devices reported that AC5™ Topical Gel (AC5™) was found to be biocompatible in testing designed to investigate subchronic systemic toxicity. The subchronic systemic testing, which involved repeat, frequent dosing over 8 weeks, is one of a panel of biocompatibility evaluation endpoints recommended by US FDA regulatory guidelines for devices such as AC5

    Read more
  • 10:22 AM

    Company achieves milestone of its first U.S. regulatory filing for a medical device FRAMINGHAM, MA–ARTH, (Marketwired – Jul 25, 2017) – Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that the Company made a 510(k) submission to the U.S. Food and Drug Administration (FDA) for its AC5™ Topical Gel on July 17, 2017. If the Company’s 510(k) application is cleared by the FDA, it is expected

    Read more
  • Arch Therapeutics
    12:52 PM

    Comments Delivered During Presentation at RHK Capital 2017 Disruptive Growth & Healthcare Conference at 10:45 a.m. ET Today FRAMINGHAM, MA– ARTH, (Marketwired – Feb 16, 2017) –  Terrence Norchi, MD, CEO of Arch Therapeutics, Inc. (OTCQB: ARTH), developer of innovative materials as hemostatic and wound care devices, provided a corporate update during a live webcast this morning at 10:45 a.m. ET at the RHK Capital 2017 Disruptive Growth & Healthcare Conference in New York City. Replays of the live webcast can

    Read more
  • 9:57 AM

    Patent Describes Use of Self-Assembling Peptidomimetics to Create Barriers that Prevent Movement of Bodily Fluids and Contaminants, as well as Other Applications FRAMINGHAM, MA–(Marketwired – Feb 2, 2017) – Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel liquid, gel and solid hemostatic and wound care devices, announced that the U.S. Patent and Trademark Office has issued a broad method-of-use patent for products that contain self-assembling peptidomimetics (U.S. Patent number 9,511,113). The patent is assigned to the

    Read more
Public Wire Banner